LU87616A1 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number: LU87616A1
Authority: LU; Luxembourg
Prior art keywords: composition according; pharmaceutically acceptable; active ingredient; compositions; composition
Prior art date: 1988-11-01

Application number

LU87616A

Other languages

English (en)

French (fr)

Inventor

Ian Robert Tapley

Original Assignee

Fisons Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-01

Filing date

1989-10-30

Publication date

1991-07-22

1989-10-30 Application filed by Fisons Plc filed Critical Fisons Plc

1991-07-22 Publication of LU87616A1 publication Critical patent/LU87616A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 8
239000000203 mixture Substances 0.000 claims description 73
239000004480 active ingredient Substances 0.000 claims description 34
239000000546 pharmaceutical excipient Substances 0.000 claims description 19
239000002671 adjuvant Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
239000000470 constituent Substances 0.000 claims description 14
150000002148 esters Chemical class 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 13
239000003085 diluting agent Substances 0.000 claims description 13
150000001408 amides Chemical class 0.000 claims description 12
239000002775 capsule Substances 0.000 claims description 9
238000000034 method Methods 0.000 claims description 8
239000002245 particle Substances 0.000 claims description 7
238000003825 pressing Methods 0.000 claims description 7
206010020772 Hypertension Diseases 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
239000006185 dispersion Substances 0.000 claims description 4
229920001187 thermosetting polymer Polymers 0.000 claims description 4
230000009974 thixotropic effect Effects 0.000 claims description 4
230000002209 hydrophobic effect Effects 0.000 claims description 2
238000004806 packaging method and process Methods 0.000 claims description 2
238000010348 incorporation Methods 0.000 claims 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
239000003826 tablet Substances 0.000 description 13
239000002585 base Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 8
239000005541 ACE inhibitor Substances 0.000 description 7
229920002261 Corn starch Polymers 0.000 description 7
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
229920000168 Microcrystalline cellulose Polymers 0.000 description 7
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 7
239000008120 corn starch Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
239000008108 microcrystalline cellulose Substances 0.000 description 7
229940016286 microcrystalline cellulose Drugs 0.000 description 7
235000019813 microcrystalline cellulose Nutrition 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 6
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 6
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
235000019700 dicalcium phosphate Nutrition 0.000 description 6
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 6
229940079832 sodium starch glycolate Drugs 0.000 description 6
239000008109 sodium starch glycolate Substances 0.000 description 6
229920003109 sodium starch glycolate Polymers 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
239000005639 Lauric acid Substances 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
229940030600 antihypertensive agent Drugs 0.000 description 4
239000002220 antihypertensive agent Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229940069328 povidone Drugs 0.000 description 4
239000007916 tablet composition Substances 0.000 description 4
AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 3
229960002003 hydrochlorothiazide Drugs 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
229940034610 toothpaste Drugs 0.000 description 3
239000000606 toothpaste Substances 0.000 description 3
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102000005862 Angiotensin II Human genes 0.000 description 2
101800000733 Angiotensin-2 Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
-1 alkali metal salts Chemical class 0.000 description 2
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
229960002576 amiloride Drugs 0.000 description 2
229950006323 angiotensin ii Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
125000005908 glyceryl ester group Chemical group 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229960004605 timolol Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000000496 Carboxypeptidases A Human genes 0.000 description 1
108010080937 Carboxypeptidases A Proteins 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000004088 foaming agent Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003906 humectant Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
229940040145 liniment Drugs 0.000 description 1
239000000865 liniment Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940069265 ophthalmic ointment Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

LU87616A 1988-11-01 1989-10-30 Compositions pharmaceutiques LU87616A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB888825541A GB8825541D0 (en)	1988-11-01	1988-11-01	Formulation
GB8825541		1988-11-01

Publications (1)

Publication Number	Publication Date
LU87616A1 true LU87616A1 (fr)	1991-07-22

Family

ID=10646121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87616A LU87616A1 (fr)	1988-11-01	1989-10-30	Compositions pharmaceutiques

Country Status (12)

Country	Link
EP (1)	EP0367509A3 (de)
JP (1)	JPH02172917A (de)
BE (1)	BE1002966A5 (de)
CA (1)	CA2001906A1 (de)
CH (1)	CH679554A5 (de)
DK (1)	DK541789A (de)
FR (1)	FR2638642A1 (de)
GB (2)	GB8825541D0 (de)
GR (1)	GR1000437B (de)
IE (1)	IE893502L (de)
LU (1)	LU87616A1 (de)
PT (1)	PT92167A (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19549852B4 (de)	1995-11-29	2009-06-04	Novartis Ag	Cyclosporin enthaltende Präparate
SE9700135D0 (sv) †	1997-01-20	1997-01-20	Astra Ab	New formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4178374A (en) *	1974-08-16	1979-12-11	Merck & Co., Inc.	Novel pharmaceutical compositions of β-blockers with diuretics
GB1590864A (en) *	1978-05-16	1981-06-10	Lilly Industries Ltd	Thixotropic filling medium for hard gelatin capsules
EP0105996A1 (de) *	1982-10-15	1984-04-25	Merck & Co. Inc.	Ophthalmische Zusammensetzung für die Behandlung von erhöhtem intraokularen Druck
ATE72431T1 (de) *	1985-08-31	1992-02-15	Fisons Plc	5-gliedrige heterocyclische angiotensinumwandlungsenzym-inhibitoren.

1988
- 1988-11-01 GB GB888825541A patent/GB8825541D0/en active Pending
1989
- 1989-10-27 EP EP19890311096 patent/EP0367509A3/de not_active Withdrawn
- 1989-10-27 GB GB8924207A patent/GB2224206B/en not_active Expired - Fee Related
- 1989-10-30 LU LU87616A patent/LU87616A1/fr unknown
- 1989-10-31 DK DK541789A patent/DK541789A/da not_active Application Discontinuation
- 1989-10-31 IE IE893502A patent/IE893502L/xx unknown
- 1989-10-31 CA CA002001906A patent/CA2001906A1/en not_active Abandoned
- 1989-10-31 FR FR8914314A patent/FR2638642A1/fr not_active Withdrawn
- 1989-10-31 BE BE8901158A patent/BE1002966A5/fr not_active IP Right Cessation
- 1989-10-31 GR GR890100710A patent/GR1000437B/el unknown
- 1989-10-31 PT PT92167A patent/PT92167A/pt unknown
- 1989-11-01 JP JP1283162A patent/JPH02172917A/ja active Pending
- 1989-11-01 CH CH3944/89A patent/CH679554A5/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
BE1002966A5 (fr)	1991-10-08
DK541789D0 (da)	1989-10-31
CA2001906A1 (en)	1990-05-01
GB8924207D0 (en)	1989-12-13
CH679554A5 (de)	1992-03-13
GR1000437B (el)	1992-07-30
GB2224206A (en)	1990-05-02
GB2224206B (en)	1992-12-09
GR890100710A (en)	1990-12-31
GB8825541D0 (en)	1988-12-07
EP0367509A2 (de)	1990-05-09
EP0367509A3 (de)	1991-05-15
DK541789A (da)	1990-05-02
JPH02172917A (ja)	1990-07-04
PT92167A (pt)	1990-05-31
IE893502L (en)	1990-05-01
FR2638642A1 (fr)	1990-05-11

Publication	Publication Date	Title
EP0862423B1 (de)	2004-09-15	Oral anzuwendende arzneizubereitung
EP1827396B1 (de)	2016-06-01	Orales medikament für die modifizierte freisetzung von mindestens einem wirkstoff in multimikrokapselform
FR2550092A1 (fr)	1985-02-08	Preparation medicamenteuse solide a deux phases et son procede d'obtention
FR2468367A1 (fr)	1981-05-08	Compositions therapeutiques a base de quinolones
WO2013027150A1 (en)	2013-02-28	Compositions and methods for the treatment of parkinson's disease
EP0369887B1 (de)	1995-06-21	Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen
JP2010515682A (ja)	2010-05-13	喘息などの５−リポキシゲナーゼ活性上昇および／またはロイコトリエン活性上昇に関連する状態における使用のためのｒ−ジロートン
BE1001706A3 (fr)	1990-02-13	Forme d'administration solide, a desagregation rapide, du diclofenac.
BE1010972A6 (fr)	1999-03-02	Composition pharmaceutique antituberculeuse et procede destine a produire ladite composition.
LU87616A1 (fr)	1991-07-22	Compositions pharmaceutiques
BE890369A (fr)	1982-03-16	Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose
CA2493074A1 (fr)	2004-02-05	Elevation du taux d'heme oxygenase avec des derives de la rheine
EP1115399B1 (de)	2005-03-02	Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten
EP0305297B1 (de)	1990-05-16	Derivate von Aza-z-bicyclooktan-caboxylsäure-3, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
FR2641971A1 (fr)	1990-07-27	Composition pharmaceutique antihypertensive associant le benazepril et un diuretique thiazidique
FR2578164A1 (fr)	1986-09-05	Utilisation de derives d'isoquinoleine et de leurs sels pour la production de compositions pharmaceutiques pour des traitements inhibant la formation de peroxydes de lipides.
EP0966276A1 (de)	1999-12-29	Verwendung von beta-3-adrenorezeptoragonisten zur herstellung von wundheilmitteln
EP1032401A2 (de)	2000-09-06	Verfahren zur hemmung der zellulären zytokinproduktion
EP0615755A1 (de)	1994-09-21	Verwendung von Tetrahydropyridinderivaten zur Herstellung von Kardioprotektiven Medikamenten
LU86973A1 (fr)	1987-12-16	Agent therapeutique pour le traitement des troubles associes a l'ischemie cerebrale
FR2650502A1 (fr)	1991-02-08	Nouvelle forme galenique orale ameliorant la biodisponibilite
MC2019A1 (fr)	1990-02-23	Composition pharmaceutique anti-hypertensive combinee
BE1001271A5 (fr)	1989-09-12	Nouvelles prostacyclines.
FR2733911A1 (fr)	1996-11-15	Composition pharmaceutique pour maladies renales ou cardio-vasculaires
BE711349A (de)	1968-08-27